Emerging targeted therapies in oral oncology: Focus on EGFR inhibition
Authors:
- Vishnu Priya VeeraraghavanVVVishnu Priya Veeraraghavan
- Shikhar DanielSDShikhar Daniel
- Arun Kumar DasariADArun Kumar Dasari
- Kaladhar Reddy AileniKAKaladhar Reddy Aileni
- Chaitra PatilCPChaitra Patil
- Santosh R. PatilSPSantosh R. Patil
Open Access
- 29 June 2024
- journal article
- review article
- Published by Elsevier in Oral Oncology Reports
- Vol. 11
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Inhibition of VEGFR2 and EGFR signaling cooperatively suppresses the proliferation of oral squamous cell carcinomaCancer Medicine, 2023
- Understanding and targeting resistance mechanisms in cancerMedcomm, 2023
- EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effectsAnais Brasileiros de Dermatologia, 2023
- Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translationAdvanced Drug Delivery Reviews, 2021
- EGFR enhances the stemness and progression of oral cancer through inhibiting autophagic degradation of SOX2Cancer Medicine, 2019
- Emerging functions of the EGFR in cancerMolecular Oncology, 2017
- EGFR targeted therapies and radiation: Optimizing efficacy by appropriate drug scheduling and patient selectionPharmacology & Therapeutics, 2015
- Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivoTargeted Oncology, 2015
- Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene, 2009
- Epidermal growth factor receptor immunohistochemistryCancer, 2008